Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk

Anna M. Bennet(University of Cambridge), John Danesh(University of Cambridge), Ulf dé Fairé(Karolinska Institutet), Anette Dahlin, Anders Ahlbom(Eastmaninstitutet), Frances Wensley, Rory Collins(University of Oxford), Zheng Ye, Emanuele Di Angelantonio(University of Cambridge), Björn Wiman, Bernard Keavney(Manchester Academic Health Science Centre)

JAMA

September 18, 2007

10.1001/jama.298.11.1300

Cited by 794

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|5.4k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents

|The Lancet|2016|2.8k

Prevalence of serious mental disorder in 7000 refugees resettled in western countries: a systematic review

|The Lancet|2005|2.3k